Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 115

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 115
---
 last to expire Licensed Patent included in the Licensed Technology; (ii)
the date of expiration of any exclusivity on the product granted by a regulatory or government body in such country; or (iii) the end
of a period of twenty (20) years from the date of the first commercial sale in such country. Should the periods referred to in items
(i) or (ii) above expire in a particular country prior to the period referred to in item (iii), above, the license in that country or
those countries shall be deemed a license to the Know-How during such post-expiration period.

Either LipoVation or Yissum may terminate the
agreement immediately upon written notice to the other relating to bankruptcy and insolvency matters, upon 90 days’ written notice
of a material breach if such breach is not cured, and upon 90 days with notice of a non-material breach, is such breach is not cured.
Notwithstanding the foregoing, a party is entitled to an extra 45 days to cure a breach if the breach is not capable of cure during the
stated period if the breaching party uses diligent good faith efforts to cure the breach. In addition, Yissum may terminate the agreement
(a) immediately if an attachment is made over our assets and/or execution proceedings are taken against us and are not set aside within
60 days of the date of attachment or proceedings, as applicable and (b) if we fail to pay, in full, the research fee under a related
sponsored research agreement upon 45 days’ notice, subject to certain exceptions. We may terminate the license agreement for any
reason on 30 days’ prior written notice to Yissum.

Termination of the agreement will result in the
termination of the license and, accordingly, the Licensed Technology and all rights included therein will revert to Yissum. All sublicenses
under the agreement are required to provide that, upon termination of the license, in whole or in part, that is, with respect to any
country, the sublicense shall terminate; provided that as long as the sublicensee is not in breach of the sublicense agreement at such
time to the extent that we would have the right to terminate the sublicense, Yissum will be required to act in one of the two following
ways: either (a) enter into a new agreement with the sublicensee upon substantially the same terms as the sublicense as long as the terms
are amended such that Yissum is not subject to any obligation